Drug Profile
Human Antithrombin III - Shandong Taibang Biological Products
Alternative Names: ATIIILatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Shandong Taibang Biological Products
- Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Antithrombin III deficiency; Thromboembolism
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Antithrombin III deficiency in China (unspecified route), prior to September 2023 (Shandong Taibang Biological Products pipeline, September 2023)
- 22 Sep 2023 Discontinued - Preclinical for Thromboembolism in China (unspecified route), prior to September 2023 (Shandong Taibang Biological Products pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Antithrombin-III-deficiency in China